FibroScan-Reproducibility and Repeatability Study
Launched by ECHOSENS · Mar 13, 2025
Trial Information
Current as of April 30, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The FibroScan-Reproducibility and Repeatability Study is looking into how reliable and consistent a non-invasive device called FibroScan is for measuring liver stiffness and fat content in patients with liver diseases, such as Non-Alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease. This study is important because detecting liver scarring early can help prevent serious complications like liver cancer. The researchers want to see if FibroScan gives similar results when used by different operators and on different days, which can improve trust in its use for monitoring liver health.
To participate in the study, adults aged 18 and older who have specific liver diseases like Metabolic Dysfunction Associated Steatotic Liver Disease or Alcohol-related Liver Disease can apply. Participants will visit the clinic twice within three days, where they will undergo multiple FibroScan scans, provide blood samples to check liver health, and fill out a brief questionnaire. Each visit will take about 25 to 45 minutes. This research, funded by the manufacturer of FibroScan, aims to enhance the understanding of how effectively the device works across various settings, ultimately benefiting those with chronic liver conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients (age ≥ 18 y.o) with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD), Metabolic and Alcohol-related Liver Disease (MetALD), and Alcohol-related Liver Disease (ALD).
- • Adult patients able to give written informed consent.
- Exclusion Criteria:
- • Vulnerable patients
- • Patients with other chronic liver disease including but not limited to hepatitis B, hepatitis C, autoimmune hepatitis, cholestatic diseases
- • Patients with ascites
- • Patients with elevated conjugated bilirubin (\>1.5 ULN)
- • Patients with heart failure
About Echosens
Echosens is a pioneering medical technology company specializing in non-invasive diagnostic solutions for liver diseases. With a commitment to improving patient outcomes, Echosens develops innovative tools that utilize advanced imaging techniques to assess liver health, enabling early detection and management of conditions such as steatosis, fibrosis, and cirrhosis. The company’s flagship product, FibroScan®, is widely recognized for its accuracy and efficiency in liver evaluation, facilitating better clinical decision-making. Through robust research and clinical trials, Echosens aims to enhance the understanding and treatment of liver diseases, ultimately contributing to the advancement of hepatology and patient care globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, England, United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported